^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Pancreatic Adenocarcinoma

    Related cancers:
    1d
    ARHGAP11A affects lung adenocarcinoma (LUAD) and pancreatic adenocarcinoma (PAAD) progression by regulating FAM83A. (PubMed, Transl Cancer Res)
    This study showed that ARHGAP11A affects the occurrence and development of LUAD and PAAD by regulating the expression of FAM83A. This study also provides a new perspective for later tumor treatment.
    Journal
    |
    LDHA (Lactate dehydrogenase A)
    1d
    A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer. (clinicaltrials.gov)
    P1/2, N=36, Recruiting, Xerient Pharma | Not yet recruiting --> Recruiting
    Enrollment open
    |
    amifostine
    2d
    From Diagnosis, Therapy Decision-Making to Genetic Risk Assessment: The Impact of ctDNA Testing on Comprehensive Cancer Management-A Case Report. (PubMed, J Natl Compr Canc Netw)
    With a primary EGFR p.L858R-mutant NSCLC, osimertinib was administered, resulting in a partial response within 10 months. In addition, given the synchronous primary pancreatic adenocarcinoma, germline testing was performed, revealing a CDKN2A p.I49T variant consistent with melanoma-pancreatic cancer syndrome, prompting comprehensive cancer surveillance and familial testing. This case illustrates how ctDNA testing enabled a comprehensive evaluation by clarifying the diagnosis, identifying actionable biomarkers, and facilitating genetic risk assessment, ultimately having a significant impact on the patient's clinical management.
    Journal • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    EGFR mutation • EGFR L858R • KRAS Q61
    |
    Tagrisso (osimertinib) • simmitinib (SYHA1817)
    3d
    A021806: Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer (clinicaltrials.gov)
    P3, N=358, Active, not recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Jan 2027 --> Dec 2028
    Trial primary completion date
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    3d
    Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial. (PubMed, Nat Commun)
    In this phase I study, we test a pooled synthetic long peptide vaccine targeting the six KRAS mutations (G12V, G12A, G12R, G12C, G12D, G13D) with ipilimumab and nivolumab in resected pancreatic adenocarcinoma. The vaccine also generates cross-reactive T cells that recognize more than one mutant KRAS antigen. These findings support the safety and diverse anti-tumor immunity of mutant KRAS vaccines (NCT04117087).
    P1 data • Journal • Checkpoint inhibition • PD(L)-1 Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12 • KRAS G13
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    4d
    Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Mayo Clinic | Trial completion date: Mar 2026 --> Oct 2028 | Trial primary completion date: Mar 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • capecitabine • albumin-bound paclitaxel
    4d
    DAPPER: Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, University Health Network, Toronto | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date • IO biomarker • Pan tumor
    |
    HRD (Homologous Recombination Deficiency)
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
    6d
    VISTA: Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (clinicaltrials.gov)
    P1, N=45, Recruiting, Baylor College of Medicine | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date • First-in-human
    |
    HER-2 positive
    |
    PATHWAY antiHer2/neu (4B5) Rabbit Monoclonal Primary Antibody
    |
    TT16
    6d
    VEINOPAN: Correlation of Portal and Peripheral Venous ctDNA in Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=40, Completed, University Hospital, Rouen | Recruiting --> Completed | N=30 --> 40 | Trial completion date: Apr 2026 --> Oct 2025 | Trial primary completion date: Apr 2026 --> Oct 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Circulating tumor DNA
    6d
    Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, First Affiliated Hospital of Wenzhou Medical University
    New P1 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • CA 19-9 (Cancer antigen 19-9)
    7d
    Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. (clinicaltrials.gov)
    P=N/A, N=101, Completed, University Hospital, Rouen | Unknown status --> Completed | Phase classification: P3 --> PN/A
    Trial completion • Phase classification
    |
    KRAS (KRAS proto-oncogene GTPase) • CA 19-9 (Cancer antigen 19-9)
    7d
    PANACHE01-PRODIGE48 Study: Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P2, N=153, Completed, University Hospital, Rouen | Unknown status --> Completed
    Trial completion
    |
    5-fluorouracil • irinotecan • leucovorin calcium